Kolltan Acquisition (Details) - Kolltan - USD ($) $ in Millions	Jul. 15, 2022	Nov. 29, 2016
Kolltan Acquisition
Shares issued as part of consideration (in shares)		1,217,200
Execution of the settlement agreement	$ 15.0
Milestone payments made in cash upon Successful Completion of a Phase 2 Clinical Trial	12.5
Milestone payment payable upon regulatory approval of a Surviving Company Product	52.5
Specified development, regulatory approvals or sales-based milestones
Kolltan Acquisition
Potential milestone payments		$ 172.5
Milestone payment payable upon regulatory approval of a Surviving Company Product	$ 172.5

Represents the business combination contingent consideration settlement agreement amount paid.

No definition available.

Name:	cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid
Namespace Prefix:	cldx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the business combination contingent consideration settlement agreement amount payable.

+ References

No definition available.

+ Details

Name:	cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable
Namespace Prefix:	cldx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash outflow for milestone payments made by the company for Successful Completion of a Clinical Trial.

+ References

No definition available.

+ Details

Name:	cldx_CashOutflowForMilestonePaymentsMadeUponSuccessfulCompletionOfClinicalTrial
Namespace Prefix:	cldx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cldx_KolltanPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=cldx_ContingentMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: